Pharmacokinetics of natural mistletoe lectins after subcutaneous injection.

PURPOSE: Knowledge of natural mistletoe lectins (nML) pharmacokinetics can be regarded as essential for further rational studies with mistletoe preparations. Studies with intravenous application of a recombinant type II ribosome inactivating protein (rML) analogous to nML revealed a short half-life of about 13 min in cancer patients. This open-label, phase I, monocenter clinical trial was performed in order to describe the pharmacokinetics of nML. METHODS: In 15 healthy male volunteers aged 18-42 years, nML were detected with a modified sandwich immuno-polymerase chain reaction (PCR) technique (Imperacer, Chimera Biotec) after single subcutaneous injection of a mistletoe extract (abnobaVISCUM(R) Fraxini 20 mg) with marketing authorization containing about 20 microg nML/ml. Secondary objectives were safety and the number of activated natural killer cells (CD54(+)/CD94(+)). RESULTS: In none of the volunteers were nML detectable before the injection, and in all volunteers, nML were detected in serum samples after injection. Individual variability, however, was large. Mean and median peak concentrations were reached 1 and 2 h after injection, respectively. In some volunteers, nML were still detectable at the final investigation 2 weeks after injection. The injection resulted in fever and flu-like symptoms in all volunteers, but no serious adverse events occurred. All symptoms and local reactions at the injection site completely disappeared within a range of 4-95 days. The number of activated natural killer (NK) cells did not change. CONCLUSIONS: Natural ML from abnobaVISCUM Fraxini 20 mg are detectable in serum after a single subcutaneous injection. Detectability is considerably longer compared with intravenously administered rML. The subcutaneous injection of this preparation without usual pretreatment with lower doses results in short-lasting fever and other flu-like symptoms.

Isolation and quantification of chitin-binding mistletoe lectin from mistletoe extracts and validation of this method.

A method was established to isolate and quantify small amounts of chitin-binding mistletoe lectin (cbML) from extracts of the mistletoe (Viscum album L.) by affinity and reverse phase high performance liquid chromatography. A validation, according to ICH guidelines, of this analytical method was carried out and showed that specificity, robustness and precision are guaranteed. In addition, linearity is ensured for a content between 0.6 and 4.1 microg/ml of cbML in the extracts and recovery was calculated to be in the range of 94 to 100%. So, accuracy of the method is guaranteed as well. As far as the range of the analytical method is concerned, a minimum of 1.2 microg and a maximum of 8.2 microg cbML can be incubated with the affinity material. Detection and quantitation limits were calculated to be 0.13 and 0.46 microg/ml cbML, respectively.

Synergism between lectins and vesicles of Viscum album L.- detection by biochemical and immunological methods.

Mistletoe (Viscum album L.) extracts, used in cancer therapy, contain several antitumor and immunologically active ingredients of which the cytotoxic mistletoe lectins and the immunoactive vesicles of chloroplast membranes are particularly important. We have investigated interactions between vesicles and lectins with respect to the question of synergistic or antagonistic effects. First we used biochemical methods. Lectin binding to vesicles was dependent on the pH-value and ionic strength of the buffers used. The strongest interaction was observed at low pH-values and at low ionic strength. Using immunological methods, we found that the combination of lectins and vesicles showed a strong amplifying synergistic effect on the stimulation of lymphocyte proliferation. We found an antagonistic effect in terms of cytotoxicity. In summary, these results demonstrate a significant influence of vesicles on all commonly used methods of determination of mistletoe lectins.